Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IGMS NASDAQ:ITCI NASDAQ:RCKT NASDAQ:SUPN NASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGMSIGM Biosciences$1.27$1.28$0.92▼$22.50$76.57M0.6480,746 shsN/AITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.57 million shsN/ARCKTRocket Pharmaceuticals$3.20-1.7%$3.18$2.19▼$22.00$344.74M0.623.57 million shs372,693 shsSUPNSupernus Pharmaceuticals$44.63+1.5%$39.91$29.16▼$46.78$2.50B0.79637,273 shs117,099 shsYMABY-mAbs Therapeutics$8.61$7.02$3.55▼$16.11$391.24M0.54723,783 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGMSIGM Biosciences0.00%0.00%0.00%+8.55%-91.98%ITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+75.22%RCKTRocket Pharmaceuticals+0.93%+1.25%+6.56%+14.84%-83.07%SUPNSupernus Pharmaceuticals0.00%-4.43%+3.05%+33.46%+39.74%YMABY-mAbs Therapeutics-0.12%+0.23%+0.94%+85.75%-33.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGMSIGM Biosciences$1.27$1.28$0.92▼$22.50$76.57M0.6480,746 shsN/AITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.57 million shsN/ARCKTRocket Pharmaceuticals$3.20-1.7%$3.18$2.19▼$22.00$344.74M0.623.57 million shs372,693 shsSUPNSupernus Pharmaceuticals$44.63+1.5%$39.91$29.16▼$46.78$2.50B0.79637,273 shs117,099 shsYMABY-mAbs Therapeutics$8.61$7.02$3.55▼$16.11$391.24M0.54723,783 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGMSIGM Biosciences0.00%0.00%0.00%+8.55%-91.98%ITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+75.22%RCKTRocket Pharmaceuticals+0.93%+1.25%+6.56%+14.84%-83.07%SUPNSupernus Pharmaceuticals0.00%-4.43%+3.05%+33.46%+39.74%YMABY-mAbs Therapeutics-0.12%+0.23%+0.94%+85.75%-33.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGMSIGM Biosciences 1.89Reduce$4.89284.95% UpsideITCIIntra-Cellular Therapies 2.20Hold$118.00-10.52% DownsideRCKTRocket Pharmaceuticals 2.41Hold$16.73423.74% UpsideSUPNSupernus Pharmaceuticals 2.50Moderate Buy$43.00-3.65% DownsideYMABY-mAbs Therapeutics 1.80Reduce$9.6211.76% UpsideCurrent Analyst Ratings BreakdownLatest ITCI, SUPN, YMAB, IGMS, and RCKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025SUPNSupernus PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$36.00 ➝ $40.008/20/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $10.008/20/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/19/2025SUPNSupernus PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/11/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.008/8/2025RCKTRocket PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$10.00 ➝ $8.008/6/2025SUPNSupernus PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$42.00 ➝ $46.008/6/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$11.00 ➝ $8.608/5/2025YMABY-mAbs TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$8.608/5/2025YMABY-mAbs TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$26.00 ➝ $8.608/5/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGMSIGM Biosciences$145.05M0.53N/AN/A$1.67 per share0.76ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/ASUPNSupernus Pharmaceuticals$661.82M3.78$4.23 per share10.55$18.76 per share2.38YMABY-mAbs Therapeutics$87.68M4.46N/AN/A$2.05 per share4.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGMSIGM Biosciences-$195.79M-$0.90N/AN/AN/A-36.81%-93.35%-24.15%11/14/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ARCKTRocket Pharmaceuticals-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)SUPNSupernus Pharmaceuticals$73.86M$1.1538.8130.99N/A9.70%14.22%10.82%11/3/2025 (Estimated)YMABY-mAbs Therapeutics-$29.67M-$0.50N/AN/AN/A-26.03%-24.60%-18.89%11/14/2025 (Estimated)Latest ITCI, SUPN, YMAB, IGMS, and RCKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025YMABY-mAbs Therapeutics-$0.27-$0.07+$0.20-$0.07$18.40 million$19.52 million8/7/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57-$0.59-$0.02-$0.62$4.36 millionN/A7/31/2025Q2 2025IGMSIGM Biosciences-$0.30$1.58+$1.88$1.58$3.20 million$143.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGMSIGM BiosciencesN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGMSIGM BiosciencesN/A17.6617.66ITCIIntra-Cellular TherapiesN/A7.667.51RCKTRocket Pharmaceuticals0.056.396.39SUPNSupernus PharmaceuticalsN/A2.582.43YMABY-mAbs TherapeuticsN/A4.003.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGMSIGM Biosciences42.79%ITCIIntra-Cellular Therapies92.33%RCKTRocket Pharmaceuticals98.39%SUPNSupernus PharmaceuticalsN/AYMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipIGMSIGM Biosciences57.00%ITCIIntra-Cellular Therapies2.60%RCKTRocket Pharmaceuticals24.76%SUPNSupernus Pharmaceuticals8.80%YMABY-mAbs Therapeutics19.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIGMSIGM Biosciences19060.29 million25.93 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableRCKTRocket Pharmaceuticals240107.90 million81.19 millionOptionableSUPNSupernus Pharmaceuticals58056.07 million51.14 millionOptionableYMABY-mAbs Therapeutics15045.44 million36.49 millionOptionableITCI, SUPN, YMAB, IGMS, and RCKT HeadlinesRecent News About These CompaniesY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Reduce" from BrokeragesSeptember 17 at 2:45 AM | marketbeat.comY-Mabs Therapeutics Completes Merger with Perseus BidCoSeptember 16 at 9:30 AM | tipranks.comJacobs Levy Equity Management Inc. Acquires 87,830 Shares of Y-mAbs Therapeutics, Inc. $YMABSeptember 14 at 3:26 AM | marketbeat.comY-mAbs Therapeutics, Inc. $YMAB Shares Bought by Cubist Systematic Strategies LLCSeptember 12, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest UpdateSeptember 9, 2025 | marketbeat.comY-Mabs Therapeutics’ Phase 2 Trial: A Potential Breakthrough for Neuroblastoma TreatmentSeptember 7, 2025 | msn.com112,483 Shares in Y-mAbs Therapeutics, Inc. $YMAB Acquired by Nuveen LLCSeptember 7, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. $YMAB Shares Bought by Wellington Management Group LLPSeptember 2, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?September 1, 2025 | zacks.comY-mAbs Therapeutics, Inc. $YMAB Stake Lifted by Acorn Capital Advisors LLCSeptember 1, 2025 | marketbeat.comStonepine Capital Management LLC Acquires New Stake in Y-mAbs Therapeutics, Inc. $YMABAugust 26, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Reduce" from AnalystsAugust 25, 2025 | marketbeat.comY-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 19, 2025 | globenewswire.comAcquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics StockAugust 13, 2025 | insidermonkey.comA Look Ahead: Y-mAbs Therapeutics's Earnings ForecastAugust 9, 2025 | benzinga.comY-mAbs (YMAB) Q2 Revenue Falls 14%August 9, 2025 | aol.comAY-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2025 | zacks.comShareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public ShareholdersAugust 8, 2025 | businesswire.comY-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsAugust 8, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)August 7, 2025 | prnewswire.comY-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 7, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeITCI, SUPN, YMAB, IGMS, and RCKT Company DescriptionsIGM Biosciences NASDAQ:IGMSIGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Intra-Cellular Therapies NASDAQ:ITCIIntra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Rocket Pharmaceuticals NASDAQ:RCKT$3.20 -0.06 (-1.69%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Supernus Pharmaceuticals NASDAQ:SUPN$44.63 +0.64 (+1.45%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.Y-mAbs Therapeutics NASDAQ:YMAB$8.61 0.00 (0.00%) As of 09/16/2025Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
